Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]DWP14012 Mass Balance in Healthy Chinese Males
NCT05868967Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fexuprazan in gastroesophageal reflux disease (GERD), sponsored by Daewoong Pharmaceutical. Primary endpoints: Time to Maximum Plasma Concentration up to 168 hours, Maximum Plasma Concentration up to 168 hours and 8 more. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05868967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868967.